Publications

@article{2022,

title = {Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data.},

author = {WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group},

url = {https://doi.org/10.1186/s12916-022-02265-9},

doi = {https://doi.org/10.1186/s12916-022-02265-9},

issn = {1741-7015},

year  = {2022},

date = {2022-03-01},

urldate = {2022-03-01},

journal = {BMC medicine},

volume = {20},

number = {1},

issue = {1},

pages = {85},

address = {England},

abstract = {BACKGROUND: Plasmodium falciparum malaria is associated with anaemia-related morbidity, attributable to host, parasite and drug factors. We quantified the haematological response following treatment of uncomplicated P. falciparum malaria to identify the factors associated with malarial anaemia. METHODS: Individual patient data from eligible antimalarial efficacy studies of uncomplicated P. falciparum malaria, available through the WorldWide Antimalarial Resistance Network data repository prior to August 2015, were pooled using standardised methodology. The haematological response over time was quantified using a multivariable linear mixed effects model with nonlinear terms for time, and the model was then used to estimate the mean haemoglobin at day of nadir and day 7. Multivariable logistic regression quantified risk factors for moderately severe anaemia (haemoglobin < 7 g/dL) at day 0, day 3 and day 7 as well as a fractional fall ≥ 25% at day 3 and day 7. RESULTS: A total of 70,226 patients, recruited into 200 studies between 1991 and 2013, were included in the analysis: 50,859 (72.4%) enrolled in Africa, 18,451 (26.3%) in Asia and 916 (1.3%) in South America. The median haemoglobin concentration at presentation was 9.9 g/dL (range 5.0-19.7 g/dL) in Africa, 11.6 g/dL (range 5.0-20.0 g/dL) in Asia and 12.3 g/dL (range 6.9-17.9 g/dL) in South America. Moderately severe anaemia (Hb < 7g/dl) was present in 8.4% (4284/50,859) of patients from Africa, 3.3% (606/18,451) from Asia and 0.1% (1/916) from South America. The nadir haemoglobin occurred on day 2 post treatment with a mean fall from baseline of 0.57 g/dL in Africa and 1.13 g/dL in Asia. Independent risk factors for moderately severe anaemia on day 7, in both Africa and Asia, included moderately severe anaemia at baseline (adjusted odds ratio (AOR) = 16.10 and AOR = 23.00, respectively), young age (age < 1 compared to ≥ 12 years AOR = 12.81 and AOR = 6.79, respectively), high parasitaemia (AOR = 1.78 and AOR = 1.58, respectively) and delayed parasite clearance (AOR = 2.44 and AOR = 2.59, respectively). In Asia, patients treated with an artemisinin-based regimen were at significantly greater risk of moderately severe anaemia on day 7 compared to those treated with a non-artemisinin-based regimen (AOR = 2.06 [95%CI 1.39-3.05], p < 0.001). CONCLUSIONS: In patients with uncomplicated P. falciparum malaria, the nadir haemoglobin occurs 2 days after starting treatment. Although artemisinin-based treatments increase the rate of parasite clearance, in Asia they are associated with a greater risk of anaemia during recovery.},

keywords = {Antimalarials, Artemisinin-based therapy, Haemoglobin, Non-artemisinin-based therapy, Plasmodium falciparum, Pooled analysis of individual patient data, Severe anaemia},

pubstate = {published},

tppubtype = {article}

}

@article{Sondo2022,

title = {Boosting the impact of seasonal malaria chemoprevention (SMC) through simultaneous screening and treatment of household members of children receiving SMC in Burkina Faso: a protocol for a randomized open label trial.},

author = {Paul Sondo and Marc Christian Tahita and Hamidou Ilboudo and Toussaint Rouamba and Karim Derra and Gauthier Tougri and Florence Ou\'{e}draogo and B\'{e}atrice Marie Ad\'{e}la\"{i}de Konseibo and Eli Roamba and Sabina Dahlstr\"{o}m Otienoburu and B\'{e}renger Kabor\'{e} and Kalynn Kennon and Kadija Ou\'{e}draogo and Wend-Timbe-Noma Arlette Ra\"{i}ssa Zongo and Fadima Yaya Bocoum and Kasia Stepniewska and Mehul Dhorda and Philippe J. Gu\'{e}rin and Halidou Tinto},

doi = {10.1186/s13690-022-00800-x},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = { Archives of Public Health},

volume = {80},

issue = {1},

pages = {41},

abstract = {BACKGROUND: Plasmodium falciparum malaria remains a major public health concern in sub-Sahara Africa. Seasonal malaria chemoprevention (SMC) with amodiaquine + sulfadoxine-pyrimethamine is one of the most important preventive interventions. Despite its implementation, the burden of malaria is still very high in children under five years old in Burkina Faso, suggesting that the expected impact of this promising strategy might not be attained. Development of innovative strategies to improve the efficacy of these existing malaria control measures is essential. In such context, we postulate that screening and treatment of malaria in household members of children receiving SMC could greatly improve the impact of SMC intervention and reduce malaria transmission in endemic settings. METHODS: This randomized superiority trial will be carried out in the Nanoro health district, Burkina Faso. The unit of randomisation will be the household and all eligible children from a household will be allocated to the same study group. Households with 3-59 months old children will be assigned to either (i) control group (SMC alone) or (ii) intervention (SMC+ screening of household members with standard Histidin Rich Protein Rapid Diagnostic Test (HRP2-RDT) and treatment if positive). The sample size will be 526 isolated households per arm, i.e., around 1052 children under SMC coverage and an expected 1315 household members. Included children will be followed-up for 24 months to fully cover two consecutive malaria transmission seasons and two SMC cycles. Children will be actively followed-up during the malaria transmission seasons while in the dry seasons the follow-up will be passive. CONCLUSION: The study will respond to a major public health concern by providing evidence of the efficacy of an innovative strategy to boost the impact of SMC intervention.},

keywords = {Africa, Amodiaquine, Burkina Faso, Chemoprevention, Dihydro artemisinin Piperaquine, Malaria, Plasmodium falciparum, Sulfadoxine-pyrimethamine},

pubstate = {published},

tppubtype = {article}

}

@article{Sondo2021-qe,

title = {Polymorphisms in Plasmodium falciparum parasites and mutations in the resistance genes Pfcrt and Pfmdr1 in Nanoro area, Burkina Faso.},

author = {Paul Sondo and Biebo Bihoun and B\'{e}renger Kabore and Marc Christian Tahita and Karim Derra and Toussaint Rouamba and Seydou Nakanabo Diallo and Adama Kazienga and Hamidou Ilboudo and Innocent Valea and Zekiba Tarnagda and Hermann Sorgho and Thierry Lefevre and Halidou Tinto},

doi = {10.11604/pamj.2021.39.118.26959},

issn = {1937-8688},

year  = {2021},

date = {2021-06-10},

urldate = {2021-06-10},

journal = {Pan Afr. Med. J.},

volume = {39},

pages = {118},

publisher = {Pan African Medical Journal},

abstract = {Introduction: from a genetic point of view P. falciparumis 

 extremely polymorphic. There is a variety of parasite strains 

 infesting individuals living in malaria endemic areas. The 

 purpose of this study is to investigate the relationship between 

 polymorphisms in Plasmodium falciparum parasites and Pfcrt and 

 Pfmdr1 gene mutations in Nanoro area, Burkina Faso. Methods: 

 blood samples from plasmodium carriers residing in the Nanoro 

 Health District were genotyped using nested PCR. Parasite gene 

 mutations associated with resistance to antimalarial drugs were 

 detected by PCR-RFLP. Results: samples of 672 patients were 

 successfully genotyped. No msp1and msp2allelic families 

 exhibited an increase in developing mutations in resistance 

 genes. However, mutant strains of these genes were present at 

 greater levels in monoclonal infections than in multi-clonal 

 infections. Conclusion: this study provides an overview of the 

 relationship between polymorphisms in Plasmodium falciparum 

 parasites and mutations in resistance genes. These data will 

 undoubtedly contribute to improving knowledge of the parasite´s 

 biology and its mechanisms of resistance to antimalarial drugs.},

note = {Copyright: Paul Sondo et al.

PMID: 34512854 

PMCID: PMC8396377},

keywords = {Antimalarials/pharmacology, Burkina Faso, Drug Resistance, Falciparum/drug therapy/parasitology, GeneticRestriction Fragment Length, Genotype, Humans, Malaria, Membrane Transport Proteins/genetics, msp1, msp2, Multidrug Resistance-Associated Proteins/genetics, Mutation, Pfcrt, Pfmdr1, Plasmodium falciparum, Plasmodium falciparum/drug effects/genetics/isolation \& purification, Polymerase Chain Reaction, Polymorphism, Protozoan Proteins/genetics},

pubstate = {published},

tppubtype = {article}

}

@article{Natama2021-ft,

title = {Genetic variation in the immune system and malaria  susceptibility in infants: a nested case-control study in  Nanoro, Burkina Faso},

author = {Hamatandi Magloire Natama and Eduard Rovira-Vallbona and Meryam Krit and Pieter Guetens and Hermann Sorgho and M Athanase Som\'{e} and Maminata Traor\'{e}-Coulibaly and Innocent Val\'{e}a and Petra F Mens and Henk D F H Schallig and Dirk Berkvens and Luc Kestens and Halidou Tinto and Anna Rosanas-Urgell},

doi = {10.1186/s12936-021-03628-y},

issn = {1475-2875},

year  = {2021},

date = {2021-02-16},

urldate = {2021-02-01},

journal = {Malar. J.},

volume = {20},

number = {1},

pages = {94},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: Genetic polymorphisms in the human immune system 

 modulate susceptibility to malaria. However, there is a paucity 

 of data on the contribution of immunogenetic variants to malaria 

 susceptibility in infants, who present differential biological 

 features related to the immaturity of their adaptive immune 

 system, the protective effect of maternal antibodies and fetal 

 haemoglobin. This study investigated the association between 

 genetic variation in innate immune response genes and malaria 

 susceptibility during the first year of life in 656 infants from 

 a birth cohort survey performed in Nanoro, Burkina Faso. 

 METHODS: Seventeen single nucleotide polymorphisms (SNPs) in 11 

 genes of the immune system previously associated with different 

 malaria phenotypes were genotyped using TaqMan allelic 

 hybridization assays in a Fluidigm platform. Plasmodium 

 falciparum infection and clinical disease were documented by 

 active and passive case detection. Case-control association 

 analyses for both alleles and genotypes were carried out using 

 univariate and multivariate logistic regression. For cytokines 

 showing significant SNP associations in multivariate analyses, 

 cord blood supernatant concentrations were measured by 

 quantitative suspension array technology (Luminex). RESULTS: 

 Genetic variants in IL-1$beta$ (rs1143634) and 

 Fc$gamma$RIIA/CD32 (rs1801274)-both in allelic, dominant and 

 co-dominant models-were significantly associated with protection 

 from both P. falciparum infection and clinical malaria. 

 Furthermore, heterozygote individuals with rs1801274 SNP in 

 Fc$gamma$RIIA/CD32 showed higher IL-1RA levels compared to wild-type homozygotes (P = 0.024), a cytokine whose production 

 is promoted by the binding of IgG immune complexes to Fc$gamma$ 

 receptors on effector immune cells. CONCLUSIONS: These findings 

 indicate that genetic polymorphisms in genes driving innate 

 immune responses are associated to malaria susceptibility during 

 the first year of life, possibly by modulating production of 

 inflammatory mediators.},

note = {PMID: 33593344 

PMCID: PMC7885350},

keywords = {Burkina Faso, Case-Control Studies, Cytokines, Falciparum/parasitology, Female, Genetic Predisposition to Disease/genetics, Humans, Immunity, Immunogenetic variants, Infant, Innate immunity, Innate/genetics, Malaria, Male, Plasmodium falciparum, Plasmodium falciparum/physiology},

pubstate = {published},

tppubtype = {article}

}

@article{Gansane2021-yh,

title = {Anti-malarial efficacy and resistance monitoring of  artemether-lumefantrine and dihydroartemisinin-piperaquine shows  inadequate efficacy in children in Burkina Faso, 2017-2018},

author = {Adama Gansan\'{e} and Leah F Moriarty and Didier M\'{e}nard and Isidore Yerbanga and Esperance Ouedraogo and Paul Sondo and Rene Kinda and Casimir Tarama and Edwige Soulama and Madou Tapsoba and David Kangoye and Cheick Said Compaore and Ousmane Badolo and Blami Dao and Samuel Tchwenko and Halidou Tinto and Innocent Valea},

doi = {10.1186/s12936-021-03585-6},

issn = {1475-2875},

year  = {2021},

date = {2021-01-19},

urldate = {2021-01-01},

journal = {Malar. J.},

volume = {20},

number = {1},

pages = {48},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: The World Health Organization recommends regularly 

 assessing the efficacy of artemisinin-based combination therapy 

 (ACT), which is a critical tool in the fight against malaria. 

 This study evaluated the efficacy of two artemisinin-based 

 combinations recommended to treat uncomplicated Plasmodium 

 falciparum malaria in Burkina Faso in three sites: Niangoloko, 

 Nanoro, and Gourcy. METHODS: This was a two-arm randomized 

 control trial of the efficacy of artemether-lumefantrine (AL) 

 and dihydroartemisinin-piperaquine (DP). Children aged 6-59 

 months old were monitored for 42 days. The primary outcomes of 

 the study were uncorrected and PCR-corrected efficacies to day 

 28 for AL and 42 for DP. Molecular markers of resistance to 

 artemisinin derivatives and partner drugs were also analysed. 

 RESULTS: Of 720 children enrolled, 672 reached study endpoints 

 at day 28, 333 in the AL arm and 339 in the DP arm. 

 PCR-corrected 28-day per protocol efficacy in the AL arm was 

 74% (64-83%) in Nanoro, 76% (66-83%) in Gourcy, and 92% 

 (84-96%) in Niangoloko. The PCR-corrected 42-day per protocol 

 efficacy in the DP arm was 84% (75-89%) in Gourcy, 89% 

 (81-94%) in Nanoro, and 97% (92-99%) in Niangoloko. No Pfk13 

 mutation previously associated with artemisinin-resistance was 

 observed. No statistically significant association was found 

 between treatment outcome and presence of the 86Y mutation in 

 the Pfmdr1 gene. There was also no association observed between 

 treatment outcome and Pfpm2 or Pfmdr1 copy number variation. 

 CONCLUSION: The results of this study indicate evidence of 

 inadequate efficacy of AL at day 28 and DP at day 42 in the same 

 two sites. A change of first-line ACT may be warranted in 

 Burkina Faso. Trial Registry Pan African Clinical Trial Registry 

 Identifier: PACTR201708002499311. Date of registration: 8/3/2017 

 https://pactr.samrc.ac.za/Search.aspx.},

keywords = {Antimalarial, Antimalarials/pharmacology, Artemether, Artemether-lumefantrine, Artemisinins/pharmacology, Burkina Faso, Child, Dihydroartemisinin-piperaquine, Drug Resistance, Efficacy, Falciparum/drug therapy, Female, Lumefantrine Drug Combination/pharmacology, Malaria, Male, Plasmodium falciparum, Preschool, Quinolines/pharmacology},

pubstate = {published},

tppubtype = {article}

}